SARS-CoV-2 Neutralizing Human Monoclonal Antibodies

Application

Monoclonal antibodies to SARS-CoV2 for use in COVID-19 diagnostics and therapeutics.

Key Benefits

Demonstrably neutralizing, important for therapeutic mAbs.
Most bind both RBG and stalk portion of spike protein, useful in case SARS-CoV2 strains develop variation in RBD.

Market Summary

Coronavirus (COVID-19) is an infectious disease that causes severe acute respiratory syndrome and led to millions of deaths. Most people infected with the SARS-CoV-2 virus experience mild to moderate respiratory illness and recover without special treatment. However, the elderly and those immunocompromised are substantially more likely to develop severe infections leading to death. Although several FDA-authorized preventative vaccines are on the market, there are limited treatments for those already infected with COVID-19. There is a significant unmet need to rapidly develop therapeutics that help treat the millions of people infected with this deadly virus and its variants.

Technical Summary

The invention consists of a novel method for the generation of monoclonal antibodies (mAb) for the purpose of being administered to SARS-CoV2 patients. During SARS-CoV2 infection mAb has the potential to neutralize the virus by blocking its receptor binding domain. Researchers generated a panel of 4 mAb from patients who were currently infected by or recovering from SARS-CoV2. The researchers then tested the mAB for their binding affinity to SARS-CoV2 spike proteins and their ability to neutralize the virus in vitro. All 4 mAB demonstrated successful binding ability to SARS-CoV2 spike proteins and its receptor binding domain. Furthermore, 3 of the mAb demonstrated neutralizing capacity.

Patent Information

App Type	Country	Serial No.	File Date	Patent Status
PCT	PCT	PCT/US2022/020322	3/15/2022	Pending
Nationalized PCT - Foreign	EP	22772028.1	3/15/2022	Pending
Nationalized PCT - United States	United States	18/282,409	9/15/2023	Pending